ARTICLE | Company News
Amgen's guidance comes up short, but migraine drug sales show promise
January 30, 2019 12:27 AM UTC
Amgen Inc. (NASDAQ:AMGN) reported 4Q18 and 2018 earnings that beat consensus estimates on Tuesday but the bellwether’s 2019 guidance fell shy of analyst expectations.
The company said it expects 2019 non-GAAP EPS of $13.10-$14.30, below consensus of $14.57. Amgen guided to $21.8-$22.9 billion in revenue for 2019. Analysts were expecting $22.91 billion...